This Site makes heavy use of JavaScript

Either you have JavaScript disabled or your browser does not support JavaScript.

To work properly, this page requires JavaScript to be enabled. If you can enable it in your browser's preferences, you may have a better experience.

Efficacy Profile | Stroke Risk Reduction in NVAF | Pradaxa® (dabigatran etexilate) Skip to main content

*Total number of strokes in the RE‑LY® Trial: 123 for PRADAXA vs. 187 for warfarin (HR: 0.64, 95% CI [0.51, 0.81] P<0.001).2
All‑cause mortality defined as: a) vascular death (i.e., cardiac, hemorrhagic, other [including fatal stroke], or unspecified); b) non‑vascular death (i.e. cancer, respiratory failure, trauma, infection, other, or unspecified); or c) death of missing/unknown cause. Non‑vascular death rates were similar in the treatment arms.1

  • References:
  • 1. Data on File. Boehringer Ingelheim Pharmaceuticals, Inc.
  • 2. Pradaxa [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.
  • 3. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L; for the Randomized Evaluation of Long‑Term Anticoagulation Therapy Investigators. Newly identified events in the RE‑LY Trial [Letter to the Editor]. N Engl J Med. 2010;363(19):1875‑1876.
  • 4. Andersen KK, Olsen TS, Dehlendorff C, Kammersgaard LP. Hemorrhagic and ischemic strokes compared: stroke severity, mortality, and risk factors. Stroke. 2009;40(6):2068‑2072.
  • 5. Hart RG, Diener H‑C, Yang S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE‑LY Trial. Stroke. 2012;43(6):1511‑1517.
  • 6. Connolly SJ, Ezekowitz MD, Yusuf S, et al; and the RE‑LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139‑1151.